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Abstract
In this study, we have evaluated the cytotoxic effect
of combining two HDAC inhibitors, SAHA and TSA,
with TRAIL in human multiple myeloma cell lines. Low
doses of SAHA or TSA enhanced the cytotoxic and
apoptotic effects of TRAIL and upregulated the surface
expression of TRAIL death receptors (DR4 and/or DR5).
SAHA and TSA induced G1 phase cell cycle growth
arrest by upregulating p21WAF1 and p27Kip1 expression
and by inhibiting E2F transcriptional activity. The en-
hanced TRAIL effect after pretreatment with HDAC in-
hibitors was consistent with the upregulation of the
proapoptotic Bcl-2 family members (Bim, Bak, Bax,
Noxa, and PUMA), the downregulation of the anti-
apoptotic members of the Bcl-2 family (Bcl-2 and
Bcl-XL), and IAPs. SAHA and TSA dissipated the mito-
chondrial membrane potential and enhanced the re-
lease of Omi/HtrA2 and AIF from the mitochondria to
the cytosol. The cytotoxic effect of both SAHA and TSA
was caspase- and calpain-independent. Inhibition of
NFKB activation by the proteasome inhibitor, MG132,
enhanced the apoptotic effect of TSA. Our study dem-
onstrated the enhancing effects of HDAC inhibitors on
apoptosis when combined with TRAIL and, for the
first time, emphasized the role of AIF in mediating the
cytotoxic effects of HDAC inhibitors.
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Introduction
Multiple myeloma, an almost incurable disease, is the sec-
ond most common blood cancer. It is characterized by the
presence of malignant plasma cells that are predominantly
located in the bone marrow. The treatment of myeloma is
mainly directed at the management of complications and
reduction of malignant cell masses. Initial chemotherapeutic
treatment could be successful; however, resistance devel-
opment urges the use of higher toxic doses accompanied by
hematopoietic stem cell transplantation [1]. Histone deacety-
lase (HDAC) inhibitors and tumor necrosis factor– related
apoptosis– inducing ligand (TRAIL) were able to induce apop-
tosis in human multiple myeloma cell lines [2]; they showed
a high degree of selectivity and were nontoxic. Furthermore,
TRAIL induced apoptosis in dexamethasone-resistant and
cytotoxic drug–resistant multiple myeloma cell [3].
TRAIL crosslinks with two death receptors, TRAIL-R1 (DR4)
and TRAIL-R2 (DR5) [4]. The crosslinking of TRAIL to DR4/
DR5 results in receptor trimerization and the recruitment of
the adapter protein FADD, through the 80–amino acid intra-
cellular death domain of the TRAIL receptor. FADD facilitates
the binding and autocatalytic activation of procaspase-8/
procaspase-10 and the formation of the death-inducing signal-
ing complex (DISC). DISC formation initiates a cascade of pro-
teolytic activation of downstream caspases and an irreversible
commitment of the cells to undergo apoptosis [5]. TRAIL-R3,
TRAIL-R4, and osteoprotegerin are other three TRAIL recep-
tors. TRAIL-R3 and TRAIL-R4 have extracellular domains
similar to DR4 and DR5, but lack a functional cytoplasmic
death domain and may serve as ‘‘decoy’’ receptors [6]. The
selectivity of TRAIL can be explained by the higher expression
of the decoy receptors (DcR1 and DcR2) in normal cells than
in tumor cells [7]. This differential expression will result in
higher DcR/DR ratio in normal cells and, consequently, lower
response to TRAIL-induced apoptosis as decoy receptors do
not transduce death signals.
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Histone acetyltransferases (HATs) and HDACs deter-
mine the acetylation status of histones and, consequently,
the chromatin structure and gene expression [8]. HDAC in-
hibitors inhibit HDACs, resulting in histone hyperacetylation
and easier access of transcription factors with consequent
increase in gene expression. Surprisingly, gene profiling
studies showed that HDAC inhibitors modulated only 2% of
the genes with a similar proportion of gene activation and
repression apoptosis [9]. Thus, HDAC inhibitors regulate
only a subset of gene expression in regulating growth, dif-
ferentiation, and apoptosis.
We have previously reported that the combination of
TRAIL with other chemotherapeutic agents (vincristine, vin-
blastine, paclitaxel, etoposide, camptothecin, and doxorubi-
cin) could inducemore apoptosis in both TRAIL-sensitive and
TRAIL-resistant cell lines [10]. In this study, we investigated
the effect of combining two HDAC inhibitors, suberoylanilide
hydroxamic acid (SAHA) and trichostatin A (TSA), with TRAIL
in human multiple myeloma cell lines. Our hypothesis is that
SAHA or TSA will augment the apoptotic effect of TRAIL by
regulating apoptosis- and cell cycle–related genes. The
purpose of this study is to investigate the molecular mecha-
nisms by which HDAC inhibitors enhance the apoptosis-
inducing potential of TRAIL in ARP-1 multiple myeloma cells.
We observed the upregulation of the TRAIL DR4/DR5 re-
ceptors, the pro-apoptotic Bcl-2 family members (Bim, Bak,
Bax, Noxa, and PUMA), the enhanced release of the mito-
chondrial proteins apoptosis-inducing factor (AIF) and Omi/
HTRA2 to the cytosol, and the upregulation of the negative
modulators of the G1 phase of the cell cycle, p21WAF1 and
p27Kip1, after treatment with SAHA or TSA. Apoptosis pro-
teins (IAPs; XIAP, cIAP1, and cIAP2) and the anti-apoptotic
members of the Bcl-2 family were downregulated after treat-
ment with SAHA or TSA. Moreover, the cytotoxic effects of
SAHA and TSA were caspase- and calpain-independent.
Finally, this study provides an insight into the mechanisms
by which HDAC inhibitors augment the cytotoxic effects of
TRAIL and induce cell cycle growth arrest, and emphasizes
the role of AIF in HDAC inhibitor–mediated apoptosis.
Materials and Methods
Reagents
The antibodies used were as follows: goat polyclonal
antibodies for acetylated histones H3 and H4, pRb, Noxa,
and PUMA b/y (Santa Cruz Biotechnology, Santa Cruz, CA);
mouse monoclonal antibodies for DR4 and DR5 receptors
(R&D Systems, Minneapolis, MN); p21WAF1 , p27Kip1 , Bax,
and AIF (Santa Cruz Biotechnology); Omi/HtrA2 (Calbio-
chem, La Jolla, CA); rabbit polyclonal antibodies for XIAP
(IMGENEX, San Diego, CA); PARP (Biosource International,
Camarillo, CA); and cIAP1, cIAP2, Bcl-XL, Bcl-2, Bak, and
Bim (Santa Cruz Biotechnology). TRAIL and SAHA were
purchased from BIOMOL (Plymouth Meeting, PA), TSA from
Alexis Biochemicals (Carlsbad, CA) and all other chemicals
used were of analytical grade from Fisher Scientific (Suwa-
nee, GA) or Sigma (St. Louis, MO).
Cell Culture
ARP-1, 8226, and MM1S cells were kindly provided by
Dr. R. Fenton (School of Medicine, University of Maryland,
Baltimore, MD). Cells were cultured in RPMI 1640 medium
(GIBCO, Grand Island, NY) supplemented with 10%
FBS (GIBCO) in a humidified incubator supplied with 5%
carbon dioxide.
Extraction of Cellular Histones
Histones were extracted according to the method of
Yoshida et al. [11]. ARP-1 cells (about 2  106 cells), treated
with SAHA or TSA for different time points, were collected
by centrifugation at 1000 rpm for 5 minutes and washed
twice with 1 phosphate-buffered saline (PBS). Cells were
suspended in 1 ml of ice-cold lysis buffer (10 mM Tris–HCl,
50 mM sodium bisulfite, 1% Triton X-100, 10 mM MgCl2,
8.6% sucrose, pH 6.5), Dounce-homogenized, and centri-
fuged at 1000g for 10 minutes to collect the nuclei, followed
by washing three times with the lysis buffer and once
with a buffer consisting of 10 mM Tris–HCl, 13 mM EDTA,
pH 7.4, successively. The pellet was suspended in 0.1 ml
of ice-cold H2O, acidified with concentrated H2SO4 to give
a final concentration of 0.4 N, and incubated at 4jC for at
least 1 hour. The suspension was centrifuged for 5 minutes
at 15,000 rpm and the supernatant was incubated overnight
with 1 ml of acetone at 20jC. The coagulated histones
were collected by centrifugation, air-dried, and dissolved in
H2O, and their concentrations were estimated by a protein
assay kit (Bio-Rad, Hercules, CA).
XTT Colorimetric Assay
XTT cell proliferation assay is a colorimetric assay for the
nonradioactive quantification of cell proliferation and viability,
where XTT (tetrazolium salt) is metabolized by viable cells
only to a water-soluble formazan dye that can be measured
spectrophotometrically [12]. Briefly, 100 ml of cell suspension
(1  106 cells/ml) was added to a 96-well plate, 100 ml of
different concentrations of the drugs (TSA, SAHA, or TRAIL
dissolved in RPMI) was added to the wells, and cells were
incubated for various time points in a humidified incubator
at 37jC and 5% CO2. A mixture of 50 ml of XTT (0.2 mg/ml)
and PMS (2.5 mM) dissolved in RPMI was added to each
well, and the cells were further incubated for 4 hours at 37jC.
Finally, the absorbance of the dye was measured spectro-
photometrically at 450 and 690 nm as a reference wave-
length. To detect the role of different caspases, serine
proteases or calpains in the cytotoxic effect of HDAC inhibi-
tors, ARP-1 cells were pretreated with 30 mM of the pan-
caspase inhibitor Z-VAD-FMK (Calbiochem), 50 mM TPCK
(Calbiochem), or 30 mM Calpeptin (Calbiochem) for 2 hours
prior to SAHA or TSA treatment, respectively.
DR4/DR5 Staining for Flow Cytometry
ARP-1 cells (1  106) were fixed with 2% Paraformal-
dehyde for 10 minutes at room temperature, washed twice
with PBS, incubated with DR4 or DR5 mouse primary anti-
body (R&D Systems) for 1 hour, washed twice with PBS, and
finally incubated with FITC-conjugated secondary antibody
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(Molecular Probes, Eugene, OR) for 30 minutes in the dark.
Fluorescence was analyzed using Becton Dickinson FACS-
can flow cytometer.
Propidium Iodide (PI) Staining for Cell Cycle Analysis
PI is a fluorescent nucleic acid binding dye that binds
preferentially to double-stranded nucleic acids, allowing
fluorescent intensity to be used as an indicator of the cel-
lular DNA content [13]. Synchronized ARP-1 and MM1S
cells were treated with SAHA (500 nM) or TSA (50 nM) for
24 hours and then fixed in 70% ethanol for 30 minutes at
4jC. Cells were washed with PBS, pretreated with RNase,
DNase-free (1 unit), for 30 minutes at 37jC, chilled on ice
to 4jC, and stained with 1 mg/ml PI in PBS. PI stained
cells were analyzed using a Becton Dickinson FACScan
flow cytometer.
Assessment of Apoptosis by Annexin V or
DAPI Staining
Annexin V FITC staining was performed as per the man-
ufacturer’s instructions (Oncogene Research, San Diego,
CA). Briefly, 1  106 ARP-1 cells were incubated with
Annexin V FITC for 15 minutes at room temperature in the
dark, and cells were centrifuged and resuspended in 1
binding buffer and PI for analysis by flow cytometry. DAPI
staining was performed by fixing of the cells with 2% pa-
raformaldehyde for 30 minutes at room temperature, incu-
bation with DAPI (0.5 mg/ml) for 20 minutes at room
temperature, washing with PBS, and finally counting of the
apoptotic nuclei using fluorescence microscopy.
RNase Protection Assay (RPA)
Total RNA was extracted using Trizol reagent (Life Tech-
nologies, Inc., Gaithersburg, MD). The RPA was performed
as per the manufacturer’s instructions (PharMingen, San
Diego, CA). Briefly, hAPO-3d multiprobe template was used
for T7 RNA polymerase-directed synthesis of [32P]UTP-
labeled antisense RNA probes. Eight micrograms of RNA
was incubated with a[32P]UTP– labeled single-stranded
RNA probes overnight at 56jC, and treated with RNase for
45 minutes at 30jC. The RNA–RNA complexes were re-
solved by electrophoresis in 6% denaturing polyacrylamide
gels and analyzed by autoradiography.
Immunoblotting
Cells were lysed in a buffer containing 10 mM Tris–HCl
(pH 7.6), 150 mM NaCl, 0.5 mM EDTA, 1 mM EGTA, 1%
SDS, 1 mM sodium orthovanadate, and a mixture of prote-
ase inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mg/ml
pepstatin A, and 2 mg/ml aprotinin). Equal amounts of lysate
protein were run on 12% SDS-PAGE gels and transferred
to PVD membrane (Perkin-Elmer, Boston, MA). PVDF blots
were blocked with 5% nonfat dry milk in TBS buffer (20 mM
Tris–HCl, pH 7.4, 500 mM NaCl), and incubated with pri-
mary antibody (diluted in TBS containing 1% BSA) overnight
at 4jC. Immunoblots were washed three times (15, 5, and
5 minutes each) with TBST (TBS and 0.01% Tween 20).
Immunoreactivity was detected by sequential incubation
with horseradish peroxidase–conjugated secondary anti-
body and ECL detection.
Subcellular Fractionation
Extraction of the cytosolic fraction was performed as
previously described [14]. Briefly, cells were harvested by
centrifugation at 1000g for 10 minutes at 4jC. The cell pellets
were washed once with ice-cold PBS and resuspended
with 5 vol of ice-cold buffer (250 mM sucrose, 20 mM
HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 17 mg/ml PMSF, 8 mg/ml aprotinin, and
2 mg/ml leupeptin, pH 7.4). Cells were homogenized with a
22-gauge needle, and the nuclei were pelleted by centri-
fugation at 750g for 10 minutes at 4jC. The supernatant
was centrifuged at 10,000g for 25 minutes. The super-
natant (cytosolic fraction) was saved for further analysis
and checked for purity by Western blot analysis using
anti–cytochrome oxidase 2 antibody. The protein concen-
trations were determined by the Bradford method (Bio-Rad).
Measurement of the Mitochondrial Membrane
Potential DWm
The mitochondrial membrane potential was determined
by the retention of JC-1 dye as previously described [15].
JC-1 exhibits potential-dependent accumulation in the mito-
chondria indicated by a fluorescence emission shift from
green (f529 nm) to red (f590 nm). Consequently, mitochon-
drial depolarization is indicated by a decrease in the red/
green fluorescence intensity ratio. ARP-1 cells (5  105)
cells were loaded with JC-1 dye (1 mg/ml) during the last
30 minutes of incubation with SAHA or TSA. Cells were
washed in PBS twice. Fluorescence was monitored in a
fluorimeter by measuring both the monomer (527-nm emis-
sion; green) and J-aggregate (590-nm emission; red) forms
of JC-1 following 488-nm excitation. DWm was calculated as
a ratio of the fluorescence of J-aggregate and monomer
forms of JC-1.
Immunofluorescence Staining
ARP-1 cells were incubated with SAHA or TSA for
12 hours, fixed with 2% paraformaldehyde, and incubated
for 1 hour at room temperature in 0.1% Triton X-100/1%
BSA in PBS to enhance permeability and to block nonspe-
cific binding. Fixed cells were incubated for 1 hour at room
temperature with AIF mouse monoclonal antibody (1:100),
washed three times with PBS, and then resuspended in a
mixture of goat anti-mouse IgG (1:2000) FITC conjugate
(Molecular Probes) and 1 mg/ml DAPI (Molecular Probes) for
45 minutes at room temperature. Cells were washed three
times in PBS and then mounted for fluorescence detection
using a Nikon Eclipse E-800 fluorescence microscope.
Electrophoretic Mobility Shift Assay (EMSA)
Double-stranded oligonucleotides containing the con-
sensus binding site for NF-nB (Promega, Madison, WI) and
E2F-1 (Santa Cruz Biotechnology) were 5V end– labeled
using polynucleotide kinase and [g-32P]dATP. Nuclear ex-
tracts (3.0 mg) from ARP-1 cells treated with 50 nM TSA were
648 Interactive Effects of HDAC Inhibitors and TRAIL Fandy et al.
Neoplasia . Vol. 7, No. 7, 2005
incubated with 1 ml of labeled oligonucleotide (20,000 cpm)
and 6 ml of incubation buffer (10 mM Tris–HCl, 40 mM NaCl,
1 mMEDTA, 1mM b-mercaptoethanol, 2% glycerol, and 2 mg
of poly(dI–dC) for 20 minutes at room temperature). The
specificity of NF-nB and E2F-1 DNA-binding activity was
confirmed by the competition with excess cold (unlabeled)
wild type. DNA–protein complexes were resolved by elec-
trophoresis in 6% nondenaturing polyacrylamide gels and
analyzed by autoradiography.
Luciferase Reporter Assay
ARP-1 cells were cotransfected with E2F1 luciferase
reporter plasmid (a generous gift from A. W. Hamburger,
University of Maryland) and a cytomegalovirus 4 promoter-
driven b–gal expression plasmid using Lipofectamine
(Invitrogen, Carlsbad, CA). Luciferase activity was mea-
sured and normalized by b–gal as per the manufacturer’s
instructions (Promega).
Statistical Analyses
Results are shown as mean ± SD. Student’s t test was
used to determine significant differences. In all cases,P < .05
was considered statistically significant.
Results
SAHA and TSA Induce the Acetylation of H3 and
H4 Histones
To verify whether the effects of SAHA or TSA were me-
diated through the hyperacetylation of histones, the effect of
SAHA (500 nM) or TSA (50 nM) on histone acetylation in
ARP-1 cells was studied. ARP-1 cells treated with SAHA or
TSA for 6 or 12 hours exhibited a significant increase in
acetylation over the control (Figure 1). Equal loading of his-
tones was confirmed by Ponceau S staining.
Low Concentration of SAHA or TSA Augments
TRAIL-Induced Apoptosis and Cytotoxicity in
Multiple Myeloma
HDAC inhibitors are known apoptosis inducers [16,17].
Cytotoxicity and apoptosis induced by pretreatment of
ARP-1 multiple myeloma cells with SAHA or TSA followed
by TRAIL were studied using XTT cell proliferation assay
and Annexin V PI staining, respectively. Pretreatment of
ARP-1 cells with different concentrations of TSA for 24 hours
followed by TRAIL (50 ng/ml or 100 ng/ml) treatment for an-
other 24 hours significantly augmented the cytotoxic effect
of TRAIL (Figure 2A). The maximum cytotoxic effect was
achieved by combining 100 nM TSA and TRAIL (50 or
100 ng/ml). Also, the pretreatment of ARP-1 cells with dif-
ferent doses of SAHA (0–1 mM) for 24 hours followed by
TRAIL (100 ng/ml) augmented TRAIL cytotoxicity, and the
combination of 1 mM SAHA and 100 ng/ml TRAIL attained
the maximum cytotoxic effect (Figure 2B).
Annexin PI staining showed that SAHA or TSA cotreat-
ment with TRAIL for 24 hours augmented the apoptotic
effect of TRAIL in ARP-1 cells (Figure 2C), indicating that pre-
treatment or cotreatment of multiple myeloma cells with
SAHA or TSA and TRAIL augments both the cytotoxic and
apoptotic activities of TRAIL. SAHA- or TSA-induced apop-
tosis was confirmed by PARP cleavage (Figure 2D). The
IC50 values for TRAIL, SAHA, and TSA in different multiple
myeloma cell lines showed that the MM1S cell line was
relatively resistant to the cytotoxic effect of TRAIL in com-
parison to other cell lines. However, the cytotoxic effect of
SAHA and TSA was comparable in all cell lines (Table 1).
Upregulation of the Surface Expression of DR4 and DR5
and Induction of G1 Phase Cell Cycle Growth Arrest
by HDAC Inhibitors
The membrane expression of the TRAIL receptors, DR4/
DR5, plays an important role in TRAIL-induced apoptosis
[10].We speculated that SAHAand TSA could upregulate the
surface expression of both receptors. Treatment of ARP-1
cells with SAHA (500 nM) or TSA (50 nM) for 24 or 48 hours
resulted in differential upregulation of the membrane ex-
pression of the DR4/DR5 receptors. SAHA treatment for
24 hours significantly upregulated the expression of both
DR4 and DR5 receptors (data not shown), with a maximum
upregulation of DR4 and DR5 after 48 hours of treatment
(Figure 3, A and B, respectively). TSA treatment for 24 hours
exhibited a differential modulation by upregulating the ex-
pression of DR4 receptor but not DR5 (Figure 3, C and D,
respectively); further treatment for up to 48 hours did not
show any further change in the expression of DR4 or DR5
(data not shown). Upregulation of DR4/DR5 receptors could
be explained by either an increase in the stability of the DR4/
DR5 proteins and/or an increase in the transcription of
their genes. The latter possibility was confirmed by the in-
crease in the mRNA transcripts of both DR4 and DR5
after SAHA or TSA treatment for 12 hours (Figure 3E ). The
induction of DR5 mRNA transcription by TSA without show-
ing an increase in the surface expression could be attributed
to the trafficking of the receptor from the cytosol to the mem-
brane, or to the absence of a direct correlation between the
level of DR5 mRNA transcript and its translated protein.
HDAC inhibitors are known to induce growth arrest, dif-
ferentiation, and/or apoptosis [18]. To gain insight into their
mechanism of growth arrest, cell cycle analysis was per-
formed to determine the phase at which SAHA or TSA
Figure 1. SAHA and TSA induce the accumulation of acetylated histones in
ARP-1 cells. ARP-1 cells were treated with SAHA (500 nM) or TSA (50 nM)
for 6 and 12 hours followed by extraction of cellular histones and Western blot
analysis to detect the levels of expression of acetylated H3 (Ac-H3) and
acetylated H4 (Ac-H4). Ponceau S staining was used to confirm the proper
loading of histones. Ctrl represents the control lane.
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induces growth arrest. Table 2 shows a significant increase
in the G1 phase population of both ARP-1 and MM1S cells
after 24 hours of SAHA (500 nM) or TSA (50 nM) treatment,
indicating a G1 phase growth arrest. To understand the
mechanism by which SAHA and TSA induce G1 phase
growth arrest, we investigated their effect on the expression
of the negative modulators of the G1 phase of the cell cycle,
p21WAF1 and p27Kip1. The expression levels of p21WAF1,
p27Kip1, and p53 were upregulated after 6 to 12 hours of
treatment with SAHA or TSA (Figure 4A). To further investi-
gate the role of p21WAF1 in the observedG1 growth arrest, the
expression of the retinoblastoma tumor suppressor protein
(pRb) wasmonitored after treatment with SAHA or TSA. pRb,
in its hypophosphorylated form, can directly bind and inacti-
vate the promoter-bound transcription factor E2F, which is
required in the progression of the cell cycle from the G1 to S
phase by activating several genes involved in DNA replication
such as DNA polymerase a, proliferating cell nuclear antigen
(PCNA), Orc1, Cdc6, and the Mcm proteins [19,20]. Both
drugs significantly decreased the expression of the hyper-
phosphorylated form of pRb (Figure 4A), which is consistent
with the early upregulation of the cdk inhibitor p21WAF1 and the
observedG1 phase growth arrest. Moreover, TSAwas able to
decrease the binding and transcriptional activity of E2F1 after
30 minutes of treatment (Figure 4, B and C, respectively),
which is consistent with the observed decrease of the hyper-
phosphorylated form of pRb.
Figure 2. SAHA and TSA augment TRAIL cytotoxic and apoptotic effects. (A) ARP-1 cells were pretreated with different TSA concentrations for 24 hours followed
by treatment with different TRAIL concentrations (50 and 100 ng/ml) for another 24 hours. XTT cell proliferation assay was used to estimate cell survival.
Percentage of survival was estimated as a percentage of the value of the untreated control. Data represent the mean for four replicates ± SD. (B) ARP-1 cells were
treated with different concentrations of SAHA for 24 hours followed by treatment with 100 ng/ml TRAIL for another 24 hours and the percentage of survival was
determined by XTT assay as described above. Data represent the mean for four replicates ± SD. (C) ARP-1 cells were treated with different concentrations of
SAHA and TSA, alone or in combination with 50 ng/ml TRAIL, for 24 hours and the percentage of apoptotic cells was determined by Annexin V staining. Data
represent the mean for four replicates ± SD. *Significant difference from the respective control at P < .05. (D) ARP-1 cells were treated with SAHA (500 nM) or TSA
(50 nM) for 24 and 48 hours and the f85 kDa cleavage product of PARP was detected by Western blot analysis. -Actin was used as a loading control. Ctrl
represents the control lane.
Table 1. IC50 Determination for TRAIL, SAHA, and TSA in Different Multiple
Myeloma Cell Lines.
Cell Line IC50
SAHA (nM) TSA (nM) TRAIL (ng/ml)
ARP-1 950 80 83
MM1S 1125 78 285
8226 1200 70 80
Cells were incubated with different concentrations of TRAIL, SAHA, or TSA
for 48 hours followed by determination of the percentage of survival using
XTT assay. The experiment was repeated four times for each concentration.
The IC50 was estimated from the percentage of survival curve.
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Involvement of the Mitochondria in HDAC
Inhibitor-Induced Apoptosis
The pro-apoptotic members of the Bcl-2 protein family
play a major role in the disruption of the mitochondrial mem-
brane potential DWm and the release of different mitochondrial
pro-apoptotic proteins [21]. ARP-1 cell treatment with SAHA
(500 nM) or TSA (50 nM) for different time intervals differen-
tially upregulated the expression of the pro-apoptoticmembers
of the Bcl-2 family: the three isoforms of Bim, Bak, Noxa,
PUMA b/y, and Bax (Figure 5A). On the contrary, the level of
expression of the anti-apoptotic Bcl-2 protein was almost
abolished by SAHA or TSA treatment for different time inter-
vals (Figure 5B). Bcl-XL showed only a slight decrease in
expression after 24-hour treatment with SAHA and a signifi-
cant decrease after 24 and 48 hours of TSA treatment.
IAPs are well-known inhibitors of apoptosis by binding to
caspases and inhibiting their activity [22]; consequently, the
degradation of IAPs will favor any apoptotic stimuli. Smac/
Diablo and Omi/HtrA2 are able to inactivate IAPs by dis-
rupting the IAP–caspase complexes and/or inducing auto-
ubiquitination and degradation of IAPs [23]. ARP-1 cell
treatment with low concentrations of SAHA (500 nM) or
TSA (50 nM) for different time intervals (12, 24, and 48 hours)
resulted in different effects on the expression level of three
different IAP proteins. SAHA treatment downregulated the
expression of cIAP1 after 48 hours only, whereas cIAP2 and
XIAP expressions were downregulated by both SAHA and
TSA in a time-dependent manner (Figure 5C).
The disruption of the DWm is accompanied by the release
of crucial mitochondrial proteins, such as Omi/HtrA2, Smac/
Diablo, and AIF, in the cytoplasm to induce apoptosis [24].
ARP-1 cell treatment with SAHA or TSA significantly lowered
DWm after 12 hours of treatment (Figure 6A).
Figure 3. SAHA and TSA upregulate the surface expression and transcription of DR4/DR5 in ARP-1 cells. ARP-1 cells were treated with SAHA (500 nM) for
48 hours and the surface expression of DR4 (A) and DR5 (B) was measured as described under the Materials and Methods section. ARP-1 cells were treated
with TSA (50 nM) for 48 hours, and the surface expression of DR4 (C) and DR5 (D) was measured. (E) ARP-1 cells were treated with SAHA (500 nM) or TSA
(50 nM) for 12 hours; total RNA was extracted to perform RPA (hAPO-3d template set) as described under the Materials and Methods section. GAPDH was used
as a loading control. Ctrl represents the control lane.
Table 2. SAHA and TSA Induce G1 Phase Cell Cycle Growth Arrest in ARP-1
and MM1S Cells.
Control SAHA TSA
ARP1
G1 31.8 ± 0.4 54 ± 0.7* 42.6 ± 0.3
S 52.6 ± 0.2 39 ± 0.8 46.4 ± 0.6
G2/M 15.6 ± 0.3 7 ± 0.2 11 ± 0.4
MM1S
G1 39.1 ± 0.4 52.9 ± 0.2* 75.6 ± 0.7*
S 41.3 ± 0.1 33.4 ± 0.2 24 ± 0.3
G2/M 19.6 ± 0.8 13.7 ± 0.5 0.4 ± 0.01
Synchronized ARP-1 and MM1S cells treated for 24 hours with SAHA
(500 nM) or TSA (50 nM) were stained with PI and the percentage of cells
in each phase of the cell cycle was determined by flow cytometry. Data
represent the mean ± SD for three experiments.
*Significant difference from the respective control at P < .05.
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The release of the mitochondrial proteins such as cyto-
chrome c, Smac/Diablo, AIF, and Omi/HtrA2 in the cytosol
stimulates a cascade of events ending in apoptosis. Omi/
HtrA2 is known to play a dual role in the induction of apoptosis
by binding to IAPs and through its serine protease activity
[25]. AIF can shuttle directly to the nucleus and induce
peripheral chromatin condensation and large-scale frag-
mentation of DNA; none of these effects is prevented by
the pan-caspase inhibitor, ZVAD-FMK [26,27]. SAHA or TSA
treatment significantly upregulated the expression of both
AIF and Omi/HtrA2 in the cytosolic fraction of ARP-1 cells
(Figure 6B). The enhanced release of Omi/HtrA2 was con-
sistent with the observed decrease in the expression levels
of the IAPs. The shuttling of AIF to the nucleus was confirmed
by immunofluorescence staining after 12 hours of treat-
ment with SAHA or TSA (Figure 6C). To determine the role
of serine proteases in SAHA- and TSA-mediated cytotoxicity,
the chymotrypsin-like serine protease inhibitor, TPCK, was
used for the pretreatment of the ARP-1 cells before SAHA
or TSA treatment. TPCK was unable to minimize or inhibit
the cytotoxic effect of SAHA or TSA (Figure 6D), indicating
that their cytotoxic effect is Omi/HtrA2–independent.
SAHA-Induced and TSA-Induced Cytotoxicities are
Caspase-Independent and Calpain-Independent
Despite the central role of caspases in the execution of
cell death, other proteins such as AIF and Omi/HtrA2 are
able to induce cell death in a caspase-independent manner
[28]. To investigate the role of different caspases in SAHA- or
TSA-mediated cytotoxic effect, ARP-1 cells were pretreated
with the pan-caspase inhibitor, Z-VAD-FMK, followed by
SAHA or TSA treatment. There was no significant change
Figure 4. HDAC inhibitors induce G1 phase growth arrest and decrease the
binding and transcriptional activity of E2F-1. (A) Synchronized ARP-1 cells
were treated with SAHA (500 nM) or TSA (50 nM) for 6, 12, and 24 hours.
The expressions of p21WAF1, p27Kip1 , p53, and phosphorylated Rb were
determined at each time point by immunoblotting. -Actin was used as a
loading control. Ctrl represents the control lane. (B) Nuclear proteins were
extracted from ARP-1 cells after treatment with TSA (50 nM) for 30 and
120 minutes, and EMSA was performed as described under the Materials
and Methods section. Cold E2F lane represents excess unlabelled E2F1
consensus sequence. (C) ARP-1 cells were transfected with E2F1 luciferase
reporter plasmid and CMV 4 promoter-driven -gal expression plasmid to
normalize the transfection efficiency. Cells were treated with TSA (50 nM) for
different time intervals (30, 60, 120, and 300 min) and the relative luciferase
activity was determined according to the manufacturer’s instructions. Data
represent the mean for three replicates ± SD. *Significant difference from the
control at P < .05.
Figure 5. Differential modulation of the expression of the pro-apoptotic and anti-apoptotic members of the Bcl-2 family and IAPs by SAHA and TSA. (A) ARP1 cells
were treated with SAHA (500 nM) or TSA (50 nM) for 12, 24, and 48 hours and the protein expression of Bim, Bak, Noxa, Bax, and PUMA /d was determined by
immunoblotting at each time point. (B) ARP-1 cells were treated with SAHA (500 nM) or TSA (50 nM) for 12, 24, and 48 hours and the protein expression of Bcl-XL
and Bcl-2 was determined by immunoblotting. -Actin was used as a loading control. Ctrl represents the control lane. (C) ARP-1 cells were treated with SAHA
500 nM or TSA 50 nM for 12, 24, and 48 hours, and the protein expression of cIAP1, cIAP2, and XIAP was determined by immunoblotting. -Actin was used as a
loading control. Ctrl represents the control lane.
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in the percentage of survival in the Z-VAD-FMK–treated or –
untreated cells, whereas TRAIL, which is known to be
caspase-dependent, showed a significant decrease in the
percentage of survival as predicted (Figure 7A). The proteo-
lytic enzyme, calpain, is also known to be activated by the
loss of mitochondrial potential [29] and can be inhibited by
calpeptin. Calpeptin pretreatment of ARP-1 cells was unable
to reduce the cytotoxicity of SAHA or TSA (Figure 7B), and
even a higher dose of calpeptin (50 mM), which was a bit toxic
to the cells by itself, did not inhibit SAHA or TSA cytotoxic
effects (data not shown).
TSA Enhances the DNA Binding Activity of NF-nB in
Myeloma Cells
Enhancing the DNA binding and transcriptional activation
of the anti-apoptotic transcription factor, NF-nB, was asso-
ciated with the ineffectiveness of HDAC inhibitors to induce
apoptosis in lung cancer [30]. TSA was not able to induce
much apoptosis in myeloma cells as shown in Figure 2C,
which could be attributed to NF-nB activation. Figure 8A
shows a significant enhancement of NF-nB binding after 60
and 120minutes of TSA (50 nM) treatment and the specificity
of binding was confirmed by the reduction in binding after
using excess unlabeled NF-nB. The inhibition of NF-nB
activity by pretreatment of ARP-1 cells with 10 mM MG132
(Calbiochem) for 1 hour significantly enhanced TSA-induced
apoptosis (Figure 8B).
Discussion
We have evaluated the effect of two HDAC inhibitors derived
from hydroxamic acid in human multiple myeloma cell lines.
SAHA and TSA induced growth arrest and apoptosis, and
augmented the apoptotic and cytotoxic effects of TRAIL.
SAHA and TSA induced the transcription and surface ex-
pression of TRAIL DR4/DR5 death receptors and the ex-
pression of the pro-apoptotic members of the Bcl-2 family.
However, the level of expression of the IAPs and the anti-
apoptotic members of the Bcl-2 family were downregulated.
Despite the central role of caspases in apoptosis induction,
SAHA and TSA cytotoxic effects were shown to be caspase-
independent and were mediated through the release of the
mitochondrial protein, AIF.
HDAC inhibitors are a new class of chemotherapeutic
drugs that are able to induce tumor cell apoptosis and/or cell
cycle arrest; however, the molecular mechanisms support-
ing their antitumor effects are not clearly understood. SAHA
was developed bymodifying the HDAC-inhibitory compound,
TSA, with a hydroxamic acid moiety as the key structural ele-
ment. Both compounds have shown efficacy in the treatment
Figure 6. Involvement of the mitochondria in SAHA- and TSA-induced apoptosis. (A) ARP-1 cells were treated with SAHA (500 nM) or TSA (50 nM) for 1, 2, 4, and
12 hours followed by staining with JC-1 dye and measurement of the mitochondrial membrane potential (DWm) as described under the Materials and Methods
section. The untreated cells (control) were assigned an arbitrary value and the value of the other treatments was estimated relative to the control. Data rep-
resent the mean for four replicates ± SD. *Significant difference from the control at P < .05. (B) ARP-1 cells were treated with SAHA (500 nM) or TSA (50 nM) for
12 and 24 hours, the cytosolic fraction was isolated, and the expression of AIF and Omi/HtrA2 was determined at each time point by immunoblotting. -Actin was
used as a loading control. (C) ARP-1 cells were treated with SAHA (500 nM) or TSA (50 nM) for 12 hours followed by double immunofluorescence staining of
the nucleus (blue color) and AIF (green) as described under the Materials and Methods section. (D) ARP-1 cells were either pretreated with TPCK (50 M) for
2 hours or left untreated, followed by treatment with SAHA (3 M) or TSA (200 nM) for 24 hours. The percentage of survival was determined by XTT assay as
described previously.
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of cancer in vivo and in vitro [9] and, because of SAHA low
toxicity, they are currently evaluated in clinical trials [31].
Previous reports have shown that the effect of HDAC inhib-
itors on gene expression was not global and only modulated
the expression of few genes [32,33]. Our working hypothesis
is that SAHA or TSA could upregulate the expression of
TRAIL death receptors DR4/DR5 and pro-apoptotic Bcl-2
family proteins, and downregulate the expression of other
anti-apoptotic proteins (Bcl-2 and IAPs); consequently, the
pretreatment or cotreatment with SAHA or TSA could aug-
ment the cytotoxic and apoptotic effect of TRAIL. Similarly,
several recent studies have shown that HDAC inhibitors can
enhance the apoptosis-inducing potential of TRAIL in leuke-
mia [34–39], breast cancer [40], melanoma [41,42], adeno-
carcinoma [43], and malignant mesothelioma [44].
A previous study has shown that the simultaneous ad-
ministration of high concentrations of SAHA (2 mM) and
TRAIL significantly increased the apoptotic activity and mito-
chondrial damage of TRAIL in human leukemia cells [45]
without any significant change in the expression of TRAIL
receptors. Other HDAC inhibitors such as LAQ824 upregu-
lated the transcription and protein expression of DR4/DR5 in
human leukemia cells [35]. Also SAHA and TSA were shown
to upregulate DR5 expression in various human malignant
tumor cells [38]. In this study, we have also shown that
pretreatment of multiple myeloma cells with SAHA or TSA
significantly increased the apoptotic and cytotoxic effects of
TRAIL. However, this effect was accompanied by a signifi-
cant increase in the membrane receptor expression of DR4/
DR5 and their mRNA transcript, indicating that the effect of
SAHA on DR4/DR5 expression is specific for each cell type
and that different HDAC inhibitors do not exhibit the same
effect on DR4/DR5 expression, although they act by the
same mechanism of action.
To further characterize the mechanisms of the TRAIL-
augmenting effect of SAHA or TSA, the effect of treatment
with low concentrations of SAHA or TSA on the expression
of the anti-apoptotic IAPs was investigated. IAPs are well-
known inhibitors of caspases; their downregulation signifi-
cantly increased apoptosis in glioma cells [46], neuroblastoma
[47], and human leukemia [48], and their upregulation
caused tumor cell resistance to drug-induced apoptosis
[49]. In this study, we have shown that cIAP-2 and XIAP ex-
pression was downregulated by SAHA and TSA in a time-
dependent manner, whereas cIAP-1 level of expression was
downregulated only after 48 hours of treatment with SAHA.
Figure 7. SAHA and TSA cytotoxic effects are caspase- and calpain-
independent. (A) ARP-1 cells were either pretreated with 30 M Z-VAD-FMK
(VAD) for 2 hours or left untreated, then different doses of SAHA, TSA, or
TRAIL (positive control) were added to both the treated and untreated cells
for 36 hours. XTT cell proliferation assay was used to estimate cell survival
and percentage of survival was estimated as a percentage of the value of the
untreated control. Pretreatment with Z-VAD-FMK. Data represent the mean
for four replicates ± SD. There was no significant difference at P < .05
between the Z-VAD-FMK–pretreated and –untreated cells after TSA or
SAHA treatment. (B) ARP-1 cells were either pretreated with 30 M calpeptin
for 2 hours or left untreated, then different doses of SAHA or TSA were added
to both the treated and untreated cells for 36 hours. XTT cell proliferation
assay was used to assess cell survival. Data represent the mean for four
replicates ± SD. No significant difference was observed between the control
and calpeptin-treated cells at P < .05.
Figure 8. TSA increases the binding activity of NF-jB in ARP-1 myeloma
cells. (A) ARP-1 cells were treated with 50 nM TSA for 0, 40, 60, and
120 minutes followed by extraction of the nuclear proteins and EMSA. The
control lane represents the negative control (no nuclear proteins) and the
cold NF-jB lane contains excess unlabeled NF-jB (100) to compete with
the labeled NF-jB for binding to nuclear proteins. (B) ARP-1 cells were
treated with MG132 (10 M) or TSA (100 nM) alone for 24 hours or pretreated
with MG132 (10 M) for 2 hours followed by TSA treatment (100 nM) for
24 hours. DAPI staining was used to assess apoptosis and the percentage
of apoptosis was estimated as a percentage of the value of the untreated
control. Data represent the mean for four replicates ± SD. *Significant dif-
ference from the respective controls at P < .05.
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The effect on the expression of XIAP and cIAP2 is in
agreement with the effect of SAHA on the MM1S multiple
myeloma cells [50] despite the fact that we used a 10 less
concentration of SAHA. Valproic acid and SAHA were also
shown to modulate survivin expression in human melanoma
cells [41]. Our data are consistent with the observed increase
in TRAIL-induced apoptosis when pretreated with SAHA or
TSA and also with the increase in Omi/HtrA2 release from
the mitochondria because IAPs are known substrates for this
serine protease [23].
Previous reports have shown that the cytotoxic effect
of SAHA is caspase-dependent in breast cancer cells [32]
and leukemia cells [51]. However, SAHA cytotoxicity was
shown to be caspase-independent and calpain-dependent
in MM1S human multiple myeloma cells [50]. In this study,
we observed that the pretreatment with the pan-caspase
inhibitor, Z-VAD-FMK, or with the calpain inhibitor, calpeptin,
did not reduce the cytotoxicity of SAHA or TSA, indicating
that SAHA or TSA cytotoxicity is caspase- and calpain-
independent in ARP-1 multiple myeloma cells. The discrep-
ancy in the role of calpain dependency in SAHA-mediated
cytotoxicity could be explained by the fact that we used a
different cell line and the effect could be cell type–specific.
Preclinical studies provided evidence that proteasome
inhibitors may be a potential treatment approach for hema-
topoietic malignancies and it was suggested that down-
regulation of NFnB pathway is the mechanism of action of
proteasome inhibitors [30]. In this study, the proteasome
inhibitor, MG-132, significantly increased the apoptotic po-
tential of TSA in myeloma cells. We have previously shown
that NFnB regulates the expression of both pro-apoptotic
(e.g., DR4, DR5, and caspase-8) and anti-apoptotic pro-
teins (e.g., IAPs, FLIP, and Bcl-XL) [52]. These factors may
determine the sensitivity of tumor cells to TRAIL- and/or
HDAC inhibitor– induced apoptosis. The observed increase
in NFnB DNA binding activity after TSA treatment is consis-
tent with the observed effect of SAHA on NFnB in human
leukemia cells [53].
Apoptosis can be induced by both mitochondrial-depen-
dent (intrinsic) and mitochondrial-independent (extrinsic)
pathways [6]. Mitochondrial membrane depolarization and
the release of different mitochondrial proteins such as cyto-
chrome c [54], Smac/DIABLO [14], Omi/HtrA2 [55], endo-
nuclease G [28], and AIF [56] appear to be the early event
in the intrinsic pathway. To investigate the mitochondrial
role in the HDAC inhibitors’ TRAIL-augmenting effect, we
observed a significant drop in the mitochondrial membrane
potential after 12 hours of SAHA or TSA treatment, which is
in agreement with other previous reports [57,58]. Based on
the abovementioned results showing SAHA and TSA cyto-
toxic effects as caspase-independent, we hypothesized that
other mitochondrial proteins such as AIF and/or Omi/HtrA2
could be released from the mitochondria and executed the
process of cell death [22,56,59]. The increase in the cytosolic
release of AIF and Omi/HtrA2 after SAHA or TSA treatment
supports our hypothesis; however, the inability of TPCK to
inhibit the cytotoxicity of SAHA or TSA and the shuttling of
AIF to the nucleus as demonstrated by immunofluorescence
supports a major role of AIF and not Omi/HtrA2 in the cyto-
toxic effect induced by SAHA or TSA. The enhanced cyto-
solic release of AIF and Omi/HtrA2 is in agreement with the
effect of different HDAC inhibitors, such as MS-275 [60] and
LAQ824 [35], in human leukemia cells.
The Bcl-2 family of proteins comprises both pro-apoptotic
and anti-apoptotic members; the anti-apoptotic members
such as Bcl-2 and Bcl-XL inhibit the release of the mito-
chondrial apoptogenic factors, whereas the pro-apoptotic
members trigger the release of such factors [24]. The pro-
apoptotic members include the BH3-only proteins (Noxa,
PUMA, Bid, Bad, and Bim) and other multiple domain pro-
teins such as Bak and Bax. In this study, we have shown that
the treatment of multiple myeloma cells with low doses of
SAHA or TSA for different time intervals selectively upregu-
lated the expression of the pro-apoptotic members of the
Bcl-2 family and downregulated the expression of the anti-
apoptotic members. Other HDAC inhibitors such as FKK228
showed an increase in the level of the BH3-only protein Bim
in human gastric MKN45 and colorectal DLD1 adenocarci-
noma cells [61]. SAHA and TSA also modulated the expres-
sion of Bcl-2 and Bcl-XL in human melanoma cells [41]. Our
data are also in agreement with the downregulation of the
expression of the anti-apoptotic members (Bcl-2 and Bcl-XL)
in pancreatic adenocarcinoma cells [62] by TSA and in
multiple myeloma cell lines [63] using the HDAC inhibitor,
depsipeptide (FR901228).
Induction of growth arrest is a main trait of HDAC inhib-
itors; however, the growth arrest phase differs among the
different HDAC inhibitors. Our data support a G1 growth
phase arrest in both ARP-1 and MM1S cells, mediated
through the upregulation of the G1 phase–negative modu-
lators p21WAF1 and p27Kip1 and transcriptional inhibition of
E2F. The observed upregulation of p21WAF1 in other multiple
myeloma cell lines by the HDAC inhibitor, LAQ824 [2], and
SAHA [50], albeit at a higher concentration, is in agreement
with our data. However, the observed p27Kip1 upregulation is
not in agreement with the unaltered level of expression
observed before by another group [50], which again could
be attributed to the different cell line used. The upregulation
of both p21WAF1 and p27Kip1 in breast cancer cell lines by
SAHA is also in agreement with our data [32].
Conclusion
We have evaluated the cytotoxic and apoptotic effects of two
HDAC inhibitors derived from hydroxamic acid in human
multiple myeloma cells. SAHA and TSA enhanced TRAIL-
induced apoptosis through: 1) upregulation of DR4 and/or
DR5 death receptors; 2) upregulation of the pro-apoptotic
proteins of the Bcl-2 family; 3) downregulation of the anti-
apoptotic members of the Bcl-2 family; 4) downregulation of
the IAPs; and 5) enhancement of AIF release from the
mitochondria. HDAC inhibitors induced G1 phase growth
arrest by: 1) upregulation of the expression of p21WAF1 and
p27Kip1; and 2) pRb hypophosphorylation and E2F transcrip-
tional inhibition. This study should arouse the attention to the
role of AIF in HDAC inhibitor– induced cytotoxicity during the
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course of clinical evaluation of these drugs and demon-
strated that combining HDAC inhibitors and TRAIL could
be a useful strategy in the treatment of multiple myeloma.
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